Citations

Clear

29 citation(s) found for "Blanc, M".

Clinical application and reporting of neurofilament quantification in neuropsychiatric disorders: an international overview
Yriarte, Jose, Zecca, Chiara, Logroscino, Giancarlo, Koertvelyessy, Peter, Tumani, Hayrettin, Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj, Fortea, Juan M., Lleó, Alberto, Santos, Gustavo A A, Borelli, Wyllians Vendramini, Amar, Elodie Bouaziz, Bigot‐Corbel, Edith, Bjerke, Maria , Pérez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Cusato, J, Fourier, Anthony , Galimberti, Daniela, Gezen‐Ak, Duygu, Florez, Silvia de las Heras, Sánchez, Juan José Hernández, Imperiale, Daniela, Kaczorowski, Flora, Khalil, Michael, Kuhle, Jens, Lewczuk, Piotr, Tsolaki, Magda, Blanc, M, Mroszko, Barbara, Rodríguez‐Álvarez, Jose, Kulczynska‐Przybik, Agnieszka, Nogueira, Léonor, Paquet, Claire, Baiardi, Simone, Parnetti, Lucilla, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen‐Maschke, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates, Tzartos, John , Unterwalder, Nadine, Vermunt, Lisa, Zetterberg, Henrik, Teunissen, C., Lehmann, Sylvain , Delaby, Constance , Ladang, Aurélie , Zecca, Chiara, Logroscino, Giancarlo , Köertvelyessy, Pèter, Tumani, Hayrettin , Parchi, Piero , Quadrio, Isabelle , Hart, Melanie , Alcolea, Daniel , Blennow, Kaj , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Borelli, Wyllians Vendramini , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Casoli, Tiziana , Chabrashvili, Tinatin, Cusato, Jessica , Dursun, Erdinç , Galimberti, Daniela , Gezen‐Ak, Duygu , Gordon, Brian A. , Gouju, Julien , Flórez, Silvia de las Heras , Herwerth, Marina , Kasuga, Kensaku , Keshavan, Ashvini , Khalil, Michael , Kühle, Jens , Leithner, Christoph , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Rodrı́guez-Álvarez, José , Musso, Giulia , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Schraen‐Maschke, Susanna , Halbgebauer, Steffen , Tzartos, S J, Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik, Teunissen, Charlotte E. , Lehmann, Sylvain

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104274 Get It

Abstract Background The quantification of Neurofilament Light chain (NfL) in blood and cerebrospinal fluid (CSF) has proven valuable for diagnosing and prognosing various neurological disorders, including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, parkinsonism, multiple sclerosis, and ischemic damage. However, there is considerable variability in clinical and laboratory practices between centers, primarily due to different contexts of use (COU), analytical methods, and the application of cutoffs or scales. Additionally, for the same biochemical profile, the interpretation and reporting of results may vary from one center to another, raising concerns about the commutability of the tests. To date, no consensus has been reached among laboratories to define the most appropriate use of cutoffs or conclusions/comments based on NfL profiles. Method This international project involves 38 laboratories across 18 countries, all specialized in the biochemical diagnosis of neurological disorders. Using a questionnaire, we obtained descriptions from each center regarding their COU, pre‐analytical and analytical protocols (including the biological fluid and methods used to quantify NfL). Through a consensus approach, we developed a harmonized strategy for the use and reporting of NfL results across different centres according to their respective COU. Results Among the centers, 63% quantified NfL in the CSF, 87% in blood and 53% in both fluids. COU were as follow: frontotemporal dementia (71%), Alzheimer disease (71%), multiple sclerosis (61%), amyotrophic lateral sclerosis (61%), psychiatric syndrome (45%), Creutzfeldt‐Jakob disease (32%), Parkinson disease (39%), peripheral neuropathy (29%), traumatic brain injury (21%), Huntington's disease (13%), amyloid transthyretin related (11%) and cardiac arrest (8%). Most of the centers define pathological cutoffs based on publications (50%) and take age into account for this purpose (42%). Reporting is mostly transmitted through numeric results (95%). Conclusion Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice.
Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey
Hydren, Jay, Jensen, Rachel, Martinez, Jorge Arturo Hurtado, Ahlstrom, Jennifer, Barnes, Mason, Costello, Caitlin, Kaur, Gurbakhash, Mohan, Meera, Cottini, Francesca, Sborov, Douglas, Kumar, Shaji, Raje, Noopur, Moreau, Philippe, Deshpande, Maithili, Gupta-Werner, Niodita, Blanc, Tonya Le, Fowler, Jessica, Banerjee, Rahul, Hydren, Jay, Jensen, Rachel, Martinez, Jorge Arturo Hurtado, Ahlstrom, Jennifer, Barnes, Mason, Costello, Caitlin, Kaur, Gurbakhash, Mohan, Meera, Cottini, Francesca, Sborov, Douglas, Kumar, Shaji, Raje, Noopur, Moreau, Philippe, Deshpande, Maithili, Gupta-Werner, Niodita, Blanc, Tonya Le, Fowler, Jessica, Banerjee, Rahul

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6354-6354

10.1182/blood-2025-6354 Get It

Abstract Background Teclistamab (Tec) and Talquetamab (Tal) are the two first FDA approved bispecific antibodies (BsAb) for the treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM). Both Tec and Tal should be initiated with step-up dosing (SUD) in an inpatient (IP) setting to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), per US label. However, standard of care practice continues to evolve and more pts receive SUD as an outpatient (OP) to reduce healthcare resource utilization and improve pt convenience. While most real-world evidence has focused on clinical and safety outcomes of pts treated with Tec and Tal, pt experience associated with these novel BsAb therapies is relatively unexplored. Methods HealthTree Foundation, a multiple myeloma pt advocacy group which provides enrolled pts with information on treatments, community groups, and research participation, surveyed RRMM patients who have received Tec or Tal. Eligible pts who completed the treatment experience survey had at least 4 months of follow-up after starting BsAb. The survey was fielded from May 2024 through June 2025. Data collection followed IRB-exempt protocols with informed consent. Results A total of 32 patients (24 Tec, 8 Tal) completed the survey. The median age was 70 years, 50% were male, and 84% were white. Most pts (n=24; 75%) received SUD at their primary oncology clinic (n=19, 59% at an academic center; n=5, 16% at local community center), and 8 (25%) at an academic center which was not their primary oncology clinic. All pts who received SUD at an academic center that was not their primary oncology clinic later transitioned to their local community clinic post-SUD and reported being satisfied or very satisfied with their transition of care experience. Overall, most pts (n= 21; 66%) received their entire step-up dosing during a single hospitalization, while some (n=6; 19%) received all doses of the SUD during separate hospitalizations for each dose. About 13% (n=4) received all SUD in an OP setting, and 3% (n=1) received SUD in a hybrid setting (mix of IP and OP). Although 85% (n=27) of the pts received IP SUD, 66% (n=21) would have preferred IP SUD in one hospitalization, while the remaining 34% (n=11) would have preferred OP or hybrid SUD. Among pts who received IP SUD (n=27), almost a quarter reported a preference for either OP (n=4; 15%) or hybrid SUD (n=2; 7%) and 78% (n=21) preferred one IP hospitalization for SUD. The factors influencing their preference for the setting of SUD in this IP sub-group were feeling more secure with IP monitoring (78%), convenience (26%), less worry about staying near healthcare centers (15%), being able to stay with their local physician (11%), staying closer to home (7%), and lower costs to the pt (4%). Among pts receiving OP SUD (n=4), 75% (n=3) preferred fully OP SUD and 25% (n=1) preferred hybrid SUD because of convenience (n=2; 50%), lower cost to pt (n=1; 25%), flexible dosing schedule (n=1; 25%), and feeling of security with IP monitoring (n=1; 25%). All the pts receiving hybrid SUD (n=1) preferred fully OP SUD due to convenience. Although Tec and Tal are subcutaneous (SC) injections, when patients were asked to compare the options of BsAbs with comparable efficacy and safety profile, they favored SC injection (n= 22; 69%) over intravenous infusion (n = 3; 9%), while 22% (n=7) had no preference for mode of drug administration. The challenges that impacted pt experience with Tec or Tal were treatment side effects (Tal pts: n=6, 75%; Tec pts: n=9, 38%) and distance or travel time to the treatment facility (Tal pts: n=2, 25%; Tec pts: n=4; 17%). Other reasons included caring for others, continuing to work, cost and insurance, lack of caregiver/care partner, being away from home, unavailability of the therapy in community setting near home, and eligibility criteria. Conclusions Most pts in this study received SUD at their primary oncology clinic. While most pts received IP SUD and preferred a single planned IP visit, one third preferred OP or hybrid SUD due to convenience. As the field moves toward OP-only SUD, this study underscores the need to consider pt preferences. There is an unmet need for community clinics providing SUD options closer to pt homes.
Spatiotemporal factors shape mosquito virus diversity and virome composition in a host and virus-dependent manner
Koh, Cassandra , Frangeul, Lionel , Blanc, Hervé , Gibaud, Aurélien, Lacritick, Annabelle Henrion, Chitale, Rohit, Boyer, Sébastien, Girod, Romain, Grau, Nina, Ngoagouni, Carine , Henrion-Lacritick, Annabelle, Chitale, Rohit , Boyer, Sébastien , Duchemin, Jean‐Bernard , Dussart, Philippe , Girod, Romain , Butković, Anamarija , Saleh, Maria‐Carla

Mayo Clinic

No container title available | September 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.09.05.674492 Get It

ABSTRACT Beyond the arboviruses they transmit to humans and animals, mosquitoes harbour diverse viral communities that shape infection and immunity dynamics. Understanding how these communities shift within mosquito populations across time and space has important implications for how we anticipate and manage arboviral disease epidemics. Here, we examined the viromes of rural and sylvatic mosquito species sampled longitudinally across two years from countries representing South America, Africa, and Southeast Asian geographies to quantify the relative contributions of host and ecological factors in shaping their virome dynamics. We found that virus diversity and virome composition are strongly influenced by host phylogeny and spatial factors and show limited temporal variation. By examining virus similarity networks across mosquito species and biogeographies, we observed frequent instances of within- and cross-genus Culex - Anopheles virus sharing in Madagascar. Taken together, these findings inform the development and implementation strategies of any virome-based vector control technology and raise new evolutionary questions on how host generalism shapes the spatial prevalence of viruses and their potential for disease emergence.
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Goldman, Jennifer G. , Leverenz, James B., Blanc‬, ‪Frederic, Halliday, Glenda M. , Kantarci, Kejal, Lewis, Simon J.G. , Medsger, Helen Bundy, O’Brien, John T. , Scholz, Sonja W. , Ikeda, Manabu , Kantarci, Kejal , Blanc, Frédéric , O'Brien, John Tiernan , Halliday, Glenda , Goldman, Jennifer G , Scholz, Sonja W , Lewis, Simon J G , Kantarci, Kejal , Boeve, Bradley F. , Galasko, Douglas , Taylor, John‐Paul , Galvin, James E. , Leverenz, James B. , Lemstra, Afina W. , Leroi, Iracema , Litvan, Irene , Aarsland, Dag , McKeith, Ian G. , Taylor, Angela E.

Mayo Clinic

Alzheimer's & Dementia | July 20, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70470 | PMID 40684248 Get It

Abstract Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease‐modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging‐Alzheimer's Association) and alpha‐synucleinopathy and dopaminergic degeneration (Neuronal α‐synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha‐synuclein (α‐synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. Highlights DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.
How much energy does overcoming air resistance cost at 4-min-mile pace?
Silva, Edson Soares da , Hoogkamer, Wouter , Kipp, Shalaya , Kram, Rodger , da Silva, Edson Soares , Kipp, Shalaya

Mayo Clinic

Journal of Applied Physiology | July 11, 2025 | Volume: 139 | Issue: 1 | Pages: 260-261

10.1152/japplphysiol.00456.2025 | PMID 40643402 Get It

Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, Constance , Martinez‐Yriarte, Jose, Zecca, Chiara , Körtvelyessy, Péter , Tumani, Hayrettin , Quadrio, Isabelle , Hart, Melanie , Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Galimberti, Daniela , Gezen‐Ak, Duygu , Gouju, Julien , Flórez, Silvia de las Heras , Sanchez, Juanjo Hernandez, Herwerth, Marina , Imperiale, Daniele , Kaczorowski, Flora, Keshavan, Ashvini , Leithner, Christoph , Blanc, M, Rodríguez, Jose Enrique Martínez, Musso, Giulia , Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates J., Tzartos, John , Unterwalder, Nadine, Lehmann, Sylvain , Keshavan, Ashvini , Galimberti, Daniela , Herwerth, Marina , Ladang, Aurélie , Logroscino, Giancarlo , Tumani, Hayrettin , Parchi, Piero , Alcolea, Daniel , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Santos, Gustavo Alves Andrade dos , Borelli, Wyllians Vendramini , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Gordon, Brian A. , Sanchez, Juanjo Hernandez, Kasuga, Kensaku , Khalil, Michael , Kühle, Jens , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Mroczko, Barbara , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Halbgebauer, Steffen , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 23, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70343 | PMID 40551293 Get It

Abstract INTRODUCTION Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post‐analytical methods used for NfL measurement in routine clinical practice across different contexts. METHODS We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements. RESULTS Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%). DISCUSSION Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice. Highlights Unique international overview of current analytical and post‐analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.
Novel Benchmark for Robotic Liver Resection – Bridging Tradition with Innovation
Pfister, Matthias , Ma, Yong , Yang, Guangchao, Li, Linqiang , Song, Xuan , Venezia, Raphael, Jeddou, Heithem , Floc’h, Bastien Le, Valverde, A. , Péru, N. , Pessaux, Patrick, Salloum, Chady , Blanc, P., Scatton, Olivier , Tzedakis, Stylianos , Fuks, David , Chaoui, Ismaël, Silva, Silvia Gomes da, Sobral, M., Centonze, Leonardo , Zhu, Zhu , Ratti, Francesca, Rompianesi, Gianluca , Shah, Jimmy, Wakabayashi, Taiga , Coelho, Fabrício Ferreira , Castillo‐Flores, Samy , Viti, Virginia, Boggi, Ugo , Han, Ho-Seong, Panaro, Fabrizio , Wakabayashi, Go, Ielpo, Benedetto , Mejia, Alejandro , Troisi, Roberto I., Choi, Gi Hong , Liu, Rong , Sucandy, Iswanto, Rela, Mohamed , D’Hondt, Mathieu , Bröering, Dieter C. , Clavien, Pierre‐Alain , Li, Zhihao , Dong, Yawen , Clavien, Pierre-Alain , Centonze, Leonardo , Li, Zhihao , Li, Zhihao, Raptis, Dimitri , Song, Xuan, Millet, Guillaume, Truant, Stéphanie , Venezia, Raphael, Pessaux, Patrick , Giannone, Fabio , Mabrut, Jean‐Yves , Mohkam, Kayvan , Cunha, António Sá , Roy, Bertrand Le , Goumard, Claire , Fuks, David , Rammohan, Ashwin , Silva, Silvia Gomes da, López‐López, Víctor , Ratti, Francesca, Marino, Rebecca , Müller, Philip C , Lee, Bo Ram , Kato, Yutaro , Polanco, Patricio Marcelo , Goh, Brian K P , Cheung, Tan To , Efanov, Mikhail G. , Machado, Marcel Cerqueira César , Herman, Paulo , Müller-Stich, Beat Peter , Starlinger, Patrick , Martinie, John B. , Aldrighetti, Luca , Chen, Guodong , Robles, R , Benedetto, Fabrizio Di , Marques, Hugo P. , Sucandy, Iswanto , Brustia, Raffaele , Soubrane, Olivier

Mayo Clinic

Annals of Surgery | May 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006759 | PMID 40391433 Get It

Objective: To establish benchmark cutoffs for robotic liver resection (R-LR), encompassing both major and minor resections, and to determine the impact of patient selection on outcomes. Background: R-LR is a key advancement in minimally invasive liver surgery but lacks standardized benchmarks, especially for minor resections. While guidelines endorse R-LR, its role in optimizing outcomes remains unclear. This study establishes the first benchmarks for R-LR, enabling comparisons across surgical modalities and refining patient selection. Methods: This retrospective, multicenter study analyzed consecutive adult patients undergoing R-LR at 30 international centers (2020–2023). Benchmark centers had an annual case volume of ≥15 R-LR. Benchmark criteria included ASA ≤2, no major comorbidities, no prior liver resections, and Child-Pugh A status. Benchmark cutoffs for 14 key outcomes were set at the 50th and 75th percentiles of median values across benchmark centers. Multivariable logistic regression identified predictors of textbook outcomes. Results: Eighteen high-volume centers contributed 4028 cases with 2632 (65.3%) meeting benchmark criteria. Malignancy was the indication in 29.6%, most commonly hepatocellular carcinoma followed by colorectal liver metastases. Major liver resection was performed in 42.6%. The distribution of Iwate difficulty scores was low (25.4%), intermediate (53.9%), advanced (15.9%), and expert (4.9%). Benchmark cutoffs were established for minor and major resection, and stratified by Iwate low (0-3), intermediate (4-6) and high (7-12): Open conversion (≤6.5% minor, ≤10.5% major), major complications within 90 days (≤5.2% minor, ≤16.7% major), R1 resection (≤9.2% minor, ≤6.7% major). Benchmark cases performed at low-volume centers were able to achieve outcomes within the corresponding benchmark cutoffs. In fact, patient selection reflected by the proportion of benchmark patients, rather than case volume, was associated with textbook outcomes. Conclusions: This study defines R-LR benchmarks, emphasizing patient selection over center volume for optimal outcomes. Benchmark cutoffs guide training and support the expansion of R-LR.
Novel Correlations Between Exhaled Breath Volatile Organic Compounds (VOCs) and Lung Function in Ultramarathon Runners: Insights from the 2019 Ultra-Trail du Month Blanc
Chou, Hung‐Hsueh , Craster, Amy, Arthur, Keith, Boyle, B., Allsworth, Max, Kelley, E.F., Schwartz, Jesse C., Ziegler, Briana, Johnson, Kenneth A. , Robach, Paul , Basset, P., Johnson, Bruce D. , Khider, A., Davies, H., Chou, H., Arthur, K., Stewart, Glenn M. , Wheatley, C.M., Fermoyle, Caitlin C. , Johnson, K., Khider, A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6817-A6817

10.1164/ajrccm.2025.211.abstracts.a6817 Get It

Abstract Rationale: Volatile organic compounds (VOCs) in exhaled breath change significantly after ultramarathons and could help monitor athletes’ physiological status to optimize training. While VOCs can reflect metabolic changes, the connection between VOCs and clinical blood and respiratory data remains unknown. In this study, we investigated how breath VOCs are linked to clinical variables that reflect the cardiovascular and respiratory system. Methods: Correlation analysis was performed between respiratory data collected in pre- and post-race samples from 24 runners who participated in the 2019 Ultra-Trail du Mont Blanc (UTMB®) ultra-marathon. Correlation analysis was then performed between these clinical data and previously published breath VOC data collected from the same individuals. Results: Clinical data indicated a slight decrease in runner's lung function post-race. Interestingly, in post-race samples, respiratory parameters vital capacity (VC) and forced expiratory volume in one second (FEV1) formed a moderate positive correlation with 2,3-butanediol (r = 0.53, r = 0.63, respectively), a compound produced by bacterial metabolism. We hypothesize that production of 2,3-butanediol results from the effect of exhaustive exercise on the gut microbiome, which may provide protection to ameliorate lung injury. Additionally, a strengthened correlation from moderate (r = 0.5 – 0.7) to strong (r > 0.7) between VC and FEV1 (r = 0.67 to r = 0.84), forced vital capacity (FVC) and maximal expiratory pressure (MEP) (r = 0.57 to r = 0.75), was observed from pre-race to post-race samples. Finally, FEV1 and MEP shifted from no correlation (r < 0.5) in pre-race to a strong correlation (r = 0.73) in post-race. Conclusion: The strengthened correlation between respiratory data in post-race samples suggests that the gut microbiome, under the effect of exercise, may have an indirect impact on both lung function and respiratory muscle function changes. Our findings support the notion that there is an intricate relationship between exhaustive exercise, altered gut microbiome activity, and lung function, and together they can influence athlete performance.
Could a female athlete run a 4-minute mile with improved aerodynamic drafting?
Silva, Edson Soares da , Hoogkamer, Wouter , Kipp, Shalaya , Kram, Rodger , da Silva, Edson Soares , Kipp, Shalaya

Mayo Clinic

Royal Society Open Science | February 25, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1098/rsos.241564 | PMID 40012757 Get It

In 2023, Faith Kipyegon set the female world record for running one mile (4:07.64). Here, we quantitatively explore if improved aerodynamic drafting could allow her to run just 3.19% faster and thus break the 4-minute mile barrier. Drafting involves other athletes (pacers) running in formation around a designated athlete to reduce the aerodynamic drag force acting on the designated runner. Drafting allows the designated athlete to run faster at the same rate of metabolic energy consumption. Our overall approach was to estimate Kipyegon’s metabolic energy consumption during her mile world record performance. Then, we used empirically established relationships between horizontal resistive force, running velocity and metabolic power to estimate how much faster she could run at the same metabolic power if the aerodynamic force was reduced via drafting. Our calculations suggest that Kipyegon could run ~3:59.37 with drafting provided by one pacer in front and one in back who change out with two other pacers at 800 m.
Association between gene expression and neurodegeneration in dementia with Lewy bodies
Baumann, Janna M., Przybelski, Scott A. , Calizzano, Francesco , Oppedal, Ketil , Kramberger, Milica G. , Habich, Annegret , Schwarz, Christopher G. , Pardini, Matteo , Inguanzo, Anna , Blanc, Frédéric , Lemstra, Afina W. , Hort, Jakub , Brendel, Matthias , Ochoa-Figueroa, M.A. , Garibotto, Valentina , Pilotto, Andrea , Boeve, Bradley F. , Aarsland, Dag , Westman, Eric , Dierks, Thomas , Kantarci, Kejal , Morbelli, Silvia , Jonkman, Laura E. , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.086838 Get It

AbstractBackgroundPatterns of regional atrophy and hypometabolism have been observed in dementia with Lewy bodies (DLB). However, determinants of regional vulnerability to structural and functional neurodegeneration remain largely unexplored. First, we investigated the association between regional gene expression and grey matter volumes in probable DLB patients. Since hypometabolism presumably precedes overt brain atrophy, we additionally investigate the association between regional gene expression and hypometabolism in DLB.MethodTo investigate the association between gene expression and regional volumes, 165 DLB patients along with 165 age‐ and sex‐matched healthy controls from three European centres and the Mayo Clinic (USA) were included. Regional volumes were quantified from MRI using SPM12 in 112 cortical, subcortical, and cerebellar brain regions, and compared between groups, using w‐scores. Regional expression data of seven genes involved in the formation and degradation of pathological protein aggregates (APOE, APP, BIN1, GBA, MAPT, SNCA, TMEM175) was extracted from six healthy donors from the Allen Human Brain Atlas and correlated with regional volumetric w‐scores. To assess the predictive value of regional gene expression on regional volumes we used Gaussian stepwise backwards linear regression including all seven genes as predictors. To investigate the association between gene expression and hypometabolism, we are currently applying the same analysis pipeline to FDG‐PET data of 139 DLB patients from 8 European centres.ResultMost brain regions showed lower volumes in DLB patients compared to healthy controls, with differences being most pronounced in occipital and parietal lobes. Regional expression of APOE correlated positively with regional volumes in DLB. Conversely, regional expression of MAPT correlated negatively with regional volumes. Both APOE and MAPT gene expression were significant predictors of regional volumes in the regression analysis. None of the other gene expression values was significantly associated with regional volumes in DLB.ConclusionOur findings show that regional expression of genes associated with the abnormal accumulation of amyloid and tau, common co‐pathologies in DLB, partially account for the brain atrophy pattern observed in DLB patients. Analyses are ongoing for the hypometabolism pattern. Our finding emphasises the relevance of co‐pathologies in predicting atrophy progression and identifying potential targets for future disease‐modifying treatments.